Inactive Instrument

Sucampo Pharmaceuticals, Inc. Share Price

Equities

Duration

Period

Style

Wall Street slips on tech sector weakness	26/12/17	RE
Mallinckrodt : to buy Sucampo for about $840 million	26/12/17	RE
Boeing : U.S. companies react cautiously to Trump victory	09/11/16	RE

SUCAMPO PHARMACEUTICALS, INC. Former SEC Attorney Willie Briscoe Investigates Sale to Mallinckrodt plc	29/12/17	BU
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference	27/11/17	GL
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference	21/11/17	GL
Sucampo to Host 2017 R&D Day on November 16 in New York	09/11/17	GL
Sucampo Reports Third Quarter 2017 Financial Results	01/11/17	GL

Apple : POINT Marchés-Wall Street finit peu changée, freinée par Apple	26/12/17
Apple : Les valeurs à suivre à Wall Street	26/12/17
Alexion Pharmaceuticals : Les valeurs à suivre à Wall Street	08/12/17
Sucampo Pharmaceuticals : La biotech américaine Sucampo envisage de se vendre	07/12/17
Sucampo Pharmaceuticals : Une nouvelle étude publiée dans PLOS ONE fait avancer la science autour du VTS 270 utilisé pour le traitement de la maladie de Niemann-Pick de type C1 (NPC-1)	19/04/17

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B